Today: 20 May 2026
AXT stock slides on China export permit delays hitting Q4 outlook — key dates ahead
11 January 2026
1 min read

AXT stock slides on China export permit delays hitting Q4 outlook — key dates ahead

New York, January 10, 2026, 18:06 (ET) — Market closed

Shares of AXT, Inc. (AXTI) ended Friday down roughly 11%, closing at $22.99, following a lowered revenue forecast for the fourth quarter. The company cited delays in Chinese export permits for indium phosphide substrates as the cause. During the session, the stock fluctuated between $21.31 and $26.27, with around 18.2 million shares traded.

The Fremont, California-based producer of compound semiconductor wafers now anticipates fourth-quarter revenue between $22.5 million and $23.5 million. This revision comes after China’s Ministry of Commerce issued fewer export control permits than initially expected. These permits are mandatory government approvals for shipping certain products out of China.

Why it matters now: indium phosphide (InP) wafers power lasers and other optics that drive data through data centers, a segment gaining ground thanks to the AI computing boom. Management stuck to its target of more than doubling InP capacity in H2 and flagged a capital raise planned for December to fund the expansion.

The updated forecast drops below the company’s previous revenue range of $27 million to $30 million. Analysts had been expecting an average of $28.77 million, FactSet data cited by TheFly shows. “We are hopeful that we will receive additional permits in the first quarter 2026,” CEO Morris Young said. TipRanks

AXTI saw big moves unusual even for a small-cap. It jumped to an intraday peak of $26.30 on Friday before slipping to $21.43, with trading volume far exceeding its average of 4.3 million shares, according to market data. The stock’s 52-week range stretches from $1.13 to $26.30.

A recent filing with the U.S. Securities and Exchange Commission on Friday provided the update.

Craig-Hallum analyst Richard Shannon stuck with a buy rating and pegged a $26 price target, Futu News reported.

B. Riley took a different stance. Analyst Dave Kang downgraded AXT from buy to neutral but bumped up his price target to $18 from $9, TheFly reported.

The decline was notable amid a robust rally in semiconductors. The PHLX semiconductor index surged 2.7% to hit an all-time high Friday, according to Reuters. “Investors are getting granular and picking the winners and losers,” said Zachary Hill, head of portfolio management at Horizon Investments. Reuters

AXT faces a clear risk. If permits continue to drag or get stricter, orders won’t turn into shipped revenue, sending quarterly results into sharp swings.

AXT will present at the 28th Annual Needham Growth Conference in New York on Jan. 14 at 3:00 p.m. ET. The company plans to release its fourth-quarter results after the market closes on Feb. 19.

Stock Market Today

  • Euronext Q1 2026 Sees Record Trading Volumes and 15.3% Revenue Growth
    May 20, 2026, 5:43 AM EDT. Euronext reported a record Q1 2026 with cash equity trading and clearing revenue up 30.8% to €123 million, driven by high market volatility and the full contribution from Euronext Athens. Total underlying revenue rose 15.3% to €528.5 million, marking the exchange's eighth consecutive quarter of double-digit growth. Average daily cash equity transaction value in April reached €16.4 billion, with a 64.1% market share. Commodities trading revenue climbed 13.9%, while FX revenue grew 5.8%. ETF trading surged 84% since September 2025, boosted by the launch of mini ETF options. Adjusted EBITDA rose 16.7% to €343.2 million, with net income up 17.7%. Euronext declared a €3.18 dividend per share, reflecting a 50% payout, payable in May.

Latest articles

Co-Diagnostics Stock Surges — Then $3 Million Financing Puts The Rally To The Test

Co-Diagnostics Stock Surges — Then $3 Million Financing Puts The Rally To The Test

20 May 2026
New York, May 20, 2026, 05:08 EDT Co-Diagnostics shares face an early test on Wednesday after the diagnostic-test developer announced a $3 million private placement hours after its stock closed up 43.8% at $1.97 on Tuesday. Extended-hours trading showed the shares down 13.3% at $1.71 before the regular Nasdaq session. The timing matters. Co-Diagnostics had rallied after saying it had completed a strategy to develop an assay, or diagnostic test, for the Bundibugyo virus behind a fast-moving Ebola outbreak in Democratic Republic of Congo and Uganda. The late financing then shifted attention to dilution and cash needs. The company said
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Wall Street Puts $150 Target on Intel in AI Push

Wall Street Puts $150 Target on Intel in AI Push

20 May 2026
Intel shares rose 2.43% to $110.80 on Tuesday, ending a five-day losing streak. The stock rebounded as analysts raised price targets, citing demand for AI server CPUs. Intel traded between $102.40 and $113.07 during the session. The Nasdaq Composite fell 0.84%, with Nvidia and AMD also down.
Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut
Previous Story

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut

Meritage Homes stock jumps 10% on Trump mortgage-bond order — what to watch next week
Next Story

Meritage Homes stock jumps 10% on Trump mortgage-bond order — what to watch next week

Go toTop